Vor Biopharma, Inc. (VOR)
Market Cap | 1.24B |
Revenue (ttm) | n/a |
Net Income (ttm) | -31.57M |
Shares Out | 35.29M |
EPS (ttm) | -0.89 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | March 5 |
Last Price | $33.37 |
Previous Close | $33.70 |
Change ($) | -0.33 |
Change (%) | -0.98% |
Day's Open | 34.24 |
Day's Range | 30.17 - 36.53 |
Day's Volume | 352,930 |
52-Week Range | 25.32 - 63.62 |
CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted t...
CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted t...
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted th...
Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced...
Vor Biopharma, a Phase 1/2 biotech developing cell therapies for hematological diseases, filed on Friday with the SEC to raise up to $150 million in an initial public offering.
Vor Biopharma, Inc. has filed to go public with an IPO on the NASDAQ.
The FDA cleared an investigational new drug application for VOR33, an engineered stem cell therapy for the treatment of patients with acute myeloid leukemia who are at high risk for relapse, a...
About VOR
Vor Biopharma is a clinical-stage cell therapy company combining a novel patient engineering approach with targeted therapies to provide a single company solution for patients suffering from hematological malignancies. For many patients, the only way to achieve durable remission or a cure is through hematopoietic stem cell transplant (HSCT). Despite undergoing HSCT, approximately 40% of acute myeloid leukemia (AML) patients relapse and face an extremely poor prognosis, with two-year survival rates of less than 20%. The traditional tumor target ... [Read more...]
Industry Biotechnology | IPO Date Feb 5, 2021 |
CEO Robert Ang, M.B.B.S. | Employees 70 |
Stock Exchange NASDAQ | Ticker Symbol VOR |